GlassScriptPhysician profile
Daniel J Mcgowan
NPI 1780667931
$8,715.72
in general payments reported to CMS, 2019-2025
24 companies · $708 in 2025
The $708 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $1,243 · 2021: $1,194 · 2022: $2,336 · 2023: $1,686 · 2024: $633 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,027.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,740.08 | 2019-2025 | Aveir, Jot Dx, Gallant |
| Astrazeneca Pharmaceuticals LP | $1,062.95 | 2019-2025 | Farxiga, Brilinta, Andexxa |
| Pfizer INC. | $984.18 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $730.83 | 2022-2025 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $670.12 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $504.66 | 2019-2025 | |
| Amgen INC. | $408.19 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $356.85 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.44 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $149.83 | 2019-2024 | |
| Inspire Medical Systems, INC. | $149.69 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $147.19 | 2020-2023 | Uptravi, Opsumit |
| Corcym INC | $110.00 | 2025 | Memo 4d |
| Boston Scientific Corporation | $103.81 | 2019-2024 | Synergy, Watchman Flx |
| Lundbeck LLC | $73.20 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $61.65 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $51.06 | 2023-2025 | Camzyos |
| Itamar Medical INC | $46.55 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $29.40 | 2019 | |
| Abiomed | $28.06 | 2019 | |
| Gilead Sciences, INC. | $20.33 | 2019 | |
| Scpharmaceuticals INC. | $19.10 | 2024 | |
| Allergan, INC. | $11.68 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $3.87 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mcgowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.